Showing 2311-2320 of 10548 results for "".
Connections for the Future of Dermatology
https://practicaldermatology.com/videos/skin-minute/connections-for-the-future-of-dermatology/54688/Frederick Beddingfield, MD, PhD, recaps the Dermatology Summit 2026, a meeting to connect innovators and investors in the field of dermatology.DWTV Extra: Raising Awareness of GPP
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-raising-awareness-of-gpp/56366/Shannon Trotter, DO, discusses the importance of awareness of generalized pustular psoriasis (GPP) and targeting IL-36, as well as GPP Awareness Day in August.DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aOrigins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).Long-Term Bimzelx Data Presented
https://practicaldermatology.com/videos/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoNew Hope for Patients with Onychomycosis
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/new-hope-for-patients-with-onychomycosis/33161/Onychomycosis, a non-self-healing fungal infection of the toenails or fingernails, is a common infection accounting for 20% of all nail diseases in adults, affecting 5% of the worldwide population.What's New in Atopic Dermatitis?
https://practicaldermatology.com/programs/practical-dermatology/whats-new-in-atopic-dermatitis/33014/Emma Guttman, MD, PhD, professor and chair of dermatology at Mount Sinai, talks about the latest developments in treatments and therapies for atopic dermatitis.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 1
https://practicaldermatology.com/videos/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-1/32757/In the first installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, provide an overview of generalized pustular psoriasis, including the unique challenges it poses, triggers associated with it, and the importance ofFDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.